Q-omics provides the consensus-scored SEMA6C profile across patient tissues and cancer cell-line models. SEMA6C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SEMA6C is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, SEMA6C RNA expression shows 19,109 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LIHC, and LSCC as cancer lineages where SEMA6C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA6C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA6C survival associations across molecular data types. SEMA6C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA6C RNA expression–survival associations across cancer types. High SEMA6C expression shows unfavorable associations in ACC, COAD, LIHC and UCEC, but favorable associations in HNSC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SEMA6C RNA expression.
This table summarizes SEMA6C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SEMA6C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA6C shows lower tumor expression in KICH, BRCA, BLCA and HNSC and higher tumor expression in LIHC and KIRC. The LIHC box plot shows higher SEMA6C RNA expression in tumor versus normal tissue (log2 FC = +1.338, t-test p < 0.001).
This table shows molecular features associated with SEMA6C in patient tissues and cancer cell lines. In patient samples, SEMA6C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA6C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
